Clinical trials: Caffeine-Related Disorders
Recurrent Ovarian Cancer
A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer
Primary objective: To evaluate the pharmacokinetic effects of fluzoparib on caffeine, S-warfarin, omeprazole, midazolam, repaglinide and bupropion in patients with recurrent ovarian cancer.
- Trial name
- NCT04718740
- Testing
- fluzoparib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Alertness
Evaluating the Impact of Energy Drink Formulas on Alertness for an Extended Period
The primary purpose of the research is to evaluate in healthy adults the time course effects of energy drink formulas containing 120 mg caffeine with varying levels of taurine and b vitamins on subjective alertness in the…
- Trial name
- NCT07400614
- Testing
- All beverages are flavor and color matched, Flavored carbonated beverage, color-matched
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Healthy Volunteers
A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants
The purpose of this study is to assess the effect of BMS-986419 on the pharmacokinetics (PK) of single doses of caffeine (CYP1A2 substrate), bupropion (CYP2B6 substrate), midazolam (CYP3A4 substrate), flurbiprofen (CYP2C9…
- Trial name
- NCT05932277
- Testing
- BMS-986419, Caffeine, Bupropion
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Caffeine Dependence
A Long-term Safety and Efficacy of EnXtra (E-AG-01) in Healthy Adults
The present study has been proposed to investigate the long-term safety and efficacy of EnXtra in healthy adults habituated to caffeine.
- Trial name
- NCT03731286
- Testing
- Alpinia Galanga, Microcellulose crystalline
- Where
- India
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Healthy Male
A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553
This is a phase I study to evaluate drug-drug interactions (DDIs) of D-1553 as a perpetrator combined with midazolam (CYP3A4 substrate), caffeine (CYP1A2 substrate), rosuvastatin (OATP1B1/OATP1B3 substrate), furosemide…
- Trial name
- NCT06105255
- Testing
- D-1553
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- InventisBio Co., Ltd
Attention
Caffeine's Effect on Attention
The purpose of this study is to determine whether caffeine improves attention.
- Trial name
- NCT02264561
- Testing
- Food
- Where
- Netherlands
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Musculoskeletal Pain
Efficacy and Safety of the Combination of Ketoprofen and Cyclobenzaprine and Caffeine in Osteomuscular Treatment
The purpose of this study is to evaluate the safety and efficacy of an association with one anti-inflammatory and one muscle relaxant plus caffeine compared to one anti-inflammatory plus caffeine in the treatment of osteomuscular…
- Trial name
- NCT02862977
- Testing
- ketoprofen and cyclobenzaprine association with caffeine, Cyclobenzaprine with caffeine
- Where
- 6 sites in Brazil
- Volunteers
- 414 people
- Sponsor
- EMS
Healthy Participants
A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants
This is a Phase 1, open-label, multiple dose, single fixed-sequence, 2-period study to evaluate the effect of abrocitinib on the pharmacokinetics (PK) of caffeine, efavirenz and omeprazole in healthy adult participants.
- Trial name
- NCT05067439
- Testing
- Abrocitinib, Omeprazole, Caffeine
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pain
A Dental Pain Study Comparing The Analgesic Efficacy Of Ibuprofen/Caffeine
An efficacy study assessing analgesic effect of ibuprofen/caffeine in post-surgical dental pain.
- Trial name
- NCT02863575
- Testing
- Ibuprofen/Caffeine, Ibuprofen
- Where
- United States
- Volunteers
- 374 people
- Sponsor
- Pfizer
Improves Daytime Energy Levels, Reduces Afternoon Energy Crashes and Midday Fatigue
A Clinical Trial to Evaluate the Effects of Adrenal Adapt on Sleep Quality, Daytime Energy, Stress Resilience, and Cognitive Performance.
This is a single-group, open-label, uncontrolled clinical trial designed to evaluate the effects of Adrenal Adapt, a commercially available dietary supplement, on sleep quality, daytime energy, stress resilience, and cognitive…
- Conditions
- Improves Daytime Energy Levels, Reduces Afternoon Energy Crashes and Midday Fatigue, Improves Overall Sleep Quality and Restorative Sleep, Helps People Fall Asleep Faster and Wake Less During the Night
- Trial name
- NCT07893561
- Testing
- Adrenal Adapt
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bioligent
Pharmacokinetics of Repaglinide, Pharmacokinetics of Caffeine
A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and Caffeine
The purpose of this study is to assess the effect of multiple doses of isavuconazole on the pharmacokinetics of Repaglinide and possible metabolites after single dose administration.
- Conditions
- Pharmacokinetics of Repaglinide, Pharmacokinetics of Caffeine, Healthy Subjects
- Trial name
- NCT02128321
- Testing
- Isavuconazole, Repaglinide, Caffeine
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Healthy
The Effect of BI 187004 on the Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) and a P Glycoprotein Substrate (Digoxin)
To assess the influence of BI 187004 on kinetics of cytochrome P450 (CYP) and P glycoprotein (P-gp) probe drugs as a means of predicting drug-drug interactions.
- Trial name
- NCT02254148
- Testing
- midazolam, caffeine, digoxin
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Myopia
Evaluation of Short Term Use of Experimental Eye Drops BHVI2, 0.02% Atropine and BHVI2 Plus 0.02% Atropine Eye Drops
To assess the one-month ocular effects of nightly application of experimental BHVI2 and 0.02% atropine eye drops either alone or in combination, in children aged between 6 to 13 years old with myopia and randomized to use of…
- Trial name
- NCT03690414
- Testing
- Experimental BHVI2, Atropine sulfate 0.02% eye drops, Combination eye drops
- Where
- Vietnam
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Hai Yen Eye Care
Moderate to Severe Plaque Psoriasis
Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates.
Phase 1, drug-drug interaction study to evaluate the effects of Briakinumab on hte pharmacokinetics of single doses of CYP substrate in subjects with moderate to severe psoriasis.
- Trial name
- NCT01260844
- Testing
- briakinumab
- Volunteers
- 12 people
- Sponsor
- Abbott
Low Back Pain
A Comparative Study Between Lysine Clonixinate+Cyclobenzaprine and Caffeine+Carisoprodol+Sodium Diclofenac+Paracetamol
Non inferiority, multicentric, double blind study whose the primary objective is to compare the effectiveness of two products in pain reduction.
- Trial name
- NCT01421433
- Testing
- Tandrilax, Dolamin Flex
- Where
- Brazil
- Volunteers
- 160 people
- Sponsor
- Farmoquimica S.A.
Hepatitis C
Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects
The primary purpose of this study is to assess the effect of the Daclatasvir/Asunaprevir/BMS-791325 fixed dose combination (FDC) tablet on the pharmacokinetics of the cocktail CYP and transporter probe substrates and to assess…
- Trial name
- NCT02045966
- Testing
- Cocktail, DCV 3DAA FDC, BMS-791325
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy Volunteers
Open-label Study to Evaluate the Effects of NST-1024 on the PK of Multiple Drugs in Healthy Subjects
Phase 1, open label study to evaluate the effects of NST-1024 on the pharmacokinetics (PK) of caffeine (and paraxanthine), flurbiprofen, omeprazole, metoprolol, and midazolam (and 1-hydroxymidazolam) in healthy male and female…
- Trial name
- NCT05368831
- Testing
- NST-1024
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- NorthSea Therapeutics B.V.
Headache, Tension-Type
A Pharmacokinetic Study of an Experimental Paracetamol Formulation
This PK study is designed to show bioequivalence between the study treatments.
- Trial name
- NCT01476176
- Testing
- Experimental paracetamol, Paracetamol marketed formulation
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Plasma Caffeine Concentration
Comparison of Plasma Caffeine Concentration After Oral Consumption of Caffeinated Beverages With Varied Bioactive Compounds in Healthy Volunteers
This is a Phase 1, double blind, randomized, controlled, cross-over trial. The primary outcome is to quantify the incremental area-under-the-concentration-curve (iAUC) for plasma caffeine after oral consumption of caffeinated…
- Trial name
- NCT04281758
- Testing
- Beverage
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Cognitive Change, Sleep Deprivation
Sleep Deprivation Study
The purpose of this study is to evaluate the measures of brain function, both neurophysiological (event-related potentials (ERPs) and functional (cognitive assessments), in response to sleep deprivation.
- Conditions
- Cognitive Change, Sleep Deprivation, Caffeine
- Trial name
- NCT05560620
- Testing
- Sleep Deprivation, Caffeine, No Caffeine
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- NeuroCatch Inc.